Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126626232 | 12662623 | 2 | F | 20160902 | 20160818 | 20160912 | EXP | CN-ROCHE-1813621 | ROCHE | ZHANG M, QIN Y-G, WANG Y-Q, LI Y-H, MA H-F AND LU H. EVALUATION OF EFFICACY AND SAFETY OF BEVACIZUMAB COMBINED WITH ALBUMIN-BOUND PACLITAXEL FOR PATIENTS WITH PLATINUM-RESISTANT OR RECURRENT OVARIAN CANCER. CHINESE JOURNAL OF CANCER PREVENTION AND TREATMENT 2016 MAR 14;23 (5):331-334. | 0.00 | F | Y | 0.00000 | 20160912 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126626232 | 12662623 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | DAYS 1 AND 15 OF 28-DAY CYCLE | U | 125085 | 10 | MG/KG | |||||||
| 126626232 | 12662623 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | U | 125085 | |||||||||||
| 126626232 | 12662623 | 3 | SS | ALBUMIN-BOUND PACLITAXEL | PACLITAXEL | 1 | Unknown | DAYS 1, 8 AND 15 OF 28 DAY CYCLE | U | 0 | 100 | MG/M**2 | |||||||
| 126626232 | 12662623 | 4 | SS | ALBUMIN-BOUND PACLITAXEL | PACLITAXEL | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126626232 | 12662623 | 1 | Ovarian cancer metastatic |
| 126626232 | 12662623 | 2 | Ovarian cancer recurrent |
| 126626232 | 12662623 | 3 | Ovarian cancer metastatic |
| 126626232 | 12662623 | 4 | Ovarian cancer recurrent |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126626232 | 12662623 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126626232 | 12662623 | Embolism | |
| 126626232 | 12662623 | Epistaxis | |
| 126626232 | 12662623 | Faeces discoloured | |
| 126626232 | 12662623 | Haemoglobin decreased | |
| 126626232 | 12662623 | Haemorrhage | |
| 126626232 | 12662623 | Hypertension | |
| 126626232 | 12662623 | Mucosal inflammation | |
| 126626232 | 12662623 | Nausea | |
| 126626232 | 12662623 | Neuropathy peripheral | |
| 126626232 | 12662623 | Platelet count decreased | |
| 126626232 | 12662623 | Proteinuria | |
| 126626232 | 12662623 | Vomiting | |
| 126626232 | 12662623 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |